Letrozol Heumann

Letrozole, the active ingredient in Letrozol Heumann, is an aromatase inhibitor presented as an oral formulation for oral use. It lowers estrogen levels and is used to treat estrogen receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozol Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole acts on estrogen‑dependent pathways in breast cancer, providing hormone‑based therapy.

- Estrogen receptor‑positive breast cancer in postmenopausal women: reduces tumor growth by lowering circulating estrogen. - Adjuvant therapy for early‑stage disease: helps prevent recurrence after surgery. - Metastatic breast cancer in postmenopausal women: slows disease progression and improves survival.

Letrozol Heumann may cause a range of adverse reactions, some of which are frequent and others rare but serious.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Joint pain: aching in knees, hips or shoulders. - Headache: mild to moderate intensity. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Osteoporosis or bone loss: increased fracture risk. - Deep vein thrombosis: painful swelling in limbs. - Pulmonary embolism: sudden shortness of breath. - Anaphylaxis: severe allergic reaction with rash, swelling, airway compromise. - Elevated cholesterol: significant rise in lipid levels.

Before initiating therapy, clinicians should evaluate several safety considerations.

- Pregnancy: contraindicated (Category X); teratogenic risk. - Breastfeeding: not recommended; drug may pass into milk. - Bone health: monitor bone mineral density, consider calcium/vitamin D. - Liver function: assess baseline enzymes and repeat as needed. - Drug interactions: review concomitant medications for CYP2C19 modifiers. - Store at ambient temperature: keep in original container, protect from moisture and light.

Letrozol Heumann can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Estrogen‑containing therapies: may diminish letrozole efficacy. - Strong CYP2C19 inhibitors (e.g., ketoconazole): increase plasma concentrations. - Strong CYP2C19 inducers (e.g., rifampicin): decrease plasma concentrations.

Moderate Interactions (Monitor Closely): - Tamoxifen: potential antagonistic effect on hormone pathways. - Anticoagulants: may heighten bleeding risk. - Corticosteroids: can affect metabolic clearance of letrozole.